The p53 gene is lost, mutated or inactivated in most human tumours (Levine et al., 1994), thus p53 has become an ideal target for the treatment of side effects of chemotherapeutic drugs without affecting anticancer ability of these drugs (Ferber, 1999). Here, TP53 is linked to neoplasm.